Author

E. T. McAnarney

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:host-pathogen & immune response· 3 Organism:mouse· 3 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Research Focus:variant calling· 2 Assay:proteomics· 1 Research Focus:variant effect prediction· 1

Frequent Co-Authors

V. D. Menachery· 4 shared R. S. Baric· 3 shared B. Yount· 2 shared H. D. Mitchell· 2 shared K. Dinnon· 2 shared K. M. Waters· 2 shared L. Gralinski· 2 shared R. Graham· 2 shared

Activity by Year

2017-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersMicrobiology

V. D. Menachery

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Endomembrane targeting of human OAS1 p46 augments antiviral activity

F. W. Soveg, J. Schwerk, N. S. Gokhale, K. Cerosaletti, J. R. Smith, E. Pairo-Castineira, A. M. Kell, A. Forero, S. A. Zaver, K. Esser-Nobis, J. Roby, T.-Y. Hsiang, S. Ozarkar, J. M. Clingan, E. T. McAnarney, , R. Savan

This study shows that the OAS1 p46 isoform, targeted to the endomembrane system, enhances antiviral activity against RNA viruses and is associated with COVID-19 severity.

bioRxiv · Apr 21, 2021Immunology

Trypsin treatment unlocks barrier for zoonotic coronaviruses infection

V. D. Menachery, K. Dinnon, B. Yount, E. T. McAnarney, L. Gralinski, A. E. Hale, R. Graham, T. D. Scobey, S. J. Anthony, L. Wang, B. S. Graham, S. H. Randell, W. I. Lipkin, R. S. Baric

This study shows that proteolytic cleavage, not receptor binding, is the main barrier for two MERS-like bat coronaviruses to infect human cells, and that trypsin treatment can overcome this barrier.

bioRxiv · Sep 16, 2019Microbiology

Combination attenuation offers strategy for live-attenuated coronavirus vaccines

V. D. Menachery, L. Gralinski, H. D. Mitchell, K. Dinnon, S. R. Leist, B. Yount, E. T. McAnarney, R. Graham, K. M. Waters, R. S. Baric

This study shows combining NSP16 mutation with other attenuating mutations creates a safe and effective live-attenuated coronavirus vaccine that works in aged mice and against heterologous challenges.

bioRxiv · Apr 28, 2018Microbiology

MERS-CoV NSP16 necessary for IFN resistance and viral pathogenesis

V. D. Menachery, L. E. Gralinski, H. D. Mitchell, K. H. Dinnon, S. R. Leist, B. L. Yount, R. L. Graham, E. T. McAnarney, K. G. Stratton, A. S. Cockrell, K. Debbink, A. C. Sims, K. M. Waters, R. S. Baric

This study shows that disrupting MERS-CoV NSP16's 2O methyl-transferase activity attenuates viral pathogenesis and provides a live attenuated vaccine platform.

bioRxiv · Aug 8, 2017Microbiology